Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
复制标题
程序性死亡配体1是一种很有前景的血液标志物，可用于预测胃癌患者的肿瘤进展及预后情况。
DOI：
10.1111/cas.13508
复制
发表时间：
2018-03
期刊：
影响因子：
5.7
通讯作者：
Natsugoe S
中科院分区：
文献类型：
--
作者：
Amatatsu M;Arigami T;Uenosono Y;Yanagita S;Uchikado Y;Kijima Y;Kurahara H;Kita Y;Mori S;Sasaki K;Omoto I;Maemura K;Ishigami S;Natsugoe S
免疫检查点抑制剂疗法已被临床引入用于几种恶性肿瘤，其有效性已被临床试验证实。特别是，程序性细胞死亡蛋白1（PD-1）和程序性死亡配体1（PD-L1）被广泛认为是与恶性肿瘤细胞的免疫逃逸机制相关的重要免疫检查点分子。此外，血液样本的液体活检具有提供简单、可重复的取样工具的临床益处。非侵入性液体活检最近被认为是预测肿瘤进展和预后的一种有前途的方法。本研究评估了胃癌患者血液标本中PD-L1 mRNA表达的临床意义。收集124例胃癌患者治疗前外周血标本。通过定量RT-PCR评价PD-L1 mRNA表达。晚期胃癌患者中程序性死亡配体1 mRNA的表达显著高于早期胃癌患者（P = 0.002）。此外，PD-L1表达与肿瘤浸润深度、远处转移和分期显著相关（分别为P = 0.001、P <0.001和P <0.001）。PD-L1高表达患者的预后显著差于PD-L1低表达患者（P <.0001）。多变量分析表明PD-L1表达是独立的预后因素。PD-L1在外周血中的表达可能为胃癌患者的肿瘤进展和疾病结局提供免疫学预测因子。
Immune checkpoint inhibitor therapy has been clinically introduced for several malignancies, and its effectiveness has been confirmed by clinical trials. In particular, programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) are widely known as important immune checkpoint molecules associated with the mechanisms of immune escape by malignant tumor cells. In addition, liquid biopsy of blood specimens has the clinical benefit of providing a simple, repeatable sampling tool. Non‐invasive liquid biopsy has recently been spotlighted as a promising approach to predicting tumor progression and prognosis. This study assessed the clinical significance of PD‐L1 mRNA expression in blood specimens obtained from patients with gastric cancer. Peripheral blood specimens were collected before treatment from 124 patients with gastric cancer. The PD‐L1 mRNA expression was evaluated by quantitative RT‐PCR. Programmed death‐ligand 1 mRNA expression was significantly higher in patients with advanced gastric cancer than in patients with early gastric cancer (P = .002). Moreover, PD‐L1 expression correlated significantly with depth of tumor invasion, distant metastasis, and stage (P = .001, P < .001, and P < .001, respectively). Patients with high PD‐L1 expression showed significantly poorer prognosis than those with low PD‐L1 expression (P < .0001). Multivariate analysis indicated PD‐L1 expression as an independent prognostic factor. Expression of PD‐L1 in peripheral blood may offer an immunological predictor of tumor progression and disease outcome in patients with gastric cancer.
登录
查看更多内容
影响因子：
3.6
作者：
Takada, Kazuki;Toyokawa, Gouji;Maehara, Yoshihiko
通讯作者：
Maehara, Yoshihiko
影响因子：
11.5
作者：
Zang, Xingxing;Allison, James P.
通讯作者：
Allison, James P.
影响因子：
45.3
作者：
Daud, Adil I.;Wolchok, Jedd D.;Hamid, Omid
通讯作者：
Hamid, Omid
影响因子：
254.7
作者：
Torre, Lindsey A.;Bray, Freddie;Jemal, Ahmedin
通讯作者：
Jemal, Ahmedin
影响因子：
2.7
作者：
Arigami T;Uenosono Y;Yanagita S;Okubo K;Kijima T;Matsushita D;Amatatsu M;Kurahara H;Maemura K;Natsugoe S
通讯作者：
Natsugoe S